Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer
Abstract
Recent studies demonstrate the role of the tumor microenvironment in tumor progression. However, strategies used to overcome the malignant phenotypes of cancer cells modulated by the microenvironment have not been thoroughly explored. In this study, we evaluated the therapeutic efficacy of a newly developed mAb targeting microfibril-associated protein 5 (MFAP5), which is secreted predominately by cancer-associated fibroblast (CAF), in ovarian and pancreatic cancer models.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2019
- Source ID
- 10.1158/1078-0432.ccr-19-0187
Entities
People
- Cecilia S. Leung
- Jianting Sheng
- Kay-Pong Yip
- Laura C. Bover
- Long Vien
- Michael J. Birrer
- Samuel C. Mok
- Stephen T.c. Wong
- Tsz-lun Yeung
Organizations
- Houston Methodist Hospital
- National Cancer Institute
- United States Department of Defense
- University of Alabama at Birmingham
- University of South Florida
- University of Texas at Austin
- Weill Cornell Medicine